Concurrent administration of granulocyte colony-stimulating factoror granulocyte-monocyte colony-stimulating factor enhancesthe biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

References

• Leget G A, Czuczman M S. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548–551
   PubMedGoogle Scholar
• Leonard J P, Link B K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002; 29: 81–86
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F J, Gada P, Repasky E A, Czuczman M S. Enhancement in the biological activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model. Blood 2002; 100: 158a
   Web of Science ®Google Scholar
• Bertram H C, Check I J, Milano M A. Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation. Am J Clin Pathol 2001; 116: 191–203
   PubMed Web of Science ®Google Scholar
• Deans J P, Schieven G L, Shu G L, Valentine M A, Gilliand L A, Aruffo A, et al. Association of tyrosine and serine kinases with B cell surface antigen CD20. J Immunol 1993; 151: 4494–4504
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter J A, Press O W. Apoptosis of malignant human B cell by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–1652
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter J A, Press O W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000; 48: 673–683
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scan J Immunol 2000; 51: 634–641
   PubMed Web of Science ®Google Scholar
• Mathas S, Rickers A, Bommert K, Dorken B, Mapara M Y. Anti-CD20 and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60: 7170–7176
   PubMed Web of Science ®Google Scholar
• Foran J M, Gupta R K, Cunningham D, Popescu R A, Goldstone A H, Sweetenham J W, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Hematol 2000; 109: 81–88
   PubMed Web of Science ®Google Scholar
• Piro L D, White C A, Grillo-Lopez A J, Janakiraman N, Saven A, Beck T M, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661
   PubMed Web of Science ®Google Scholar
• Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Cohen R, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose, 22 day treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Clynes R A, Towers T L, Presta L G, Ravetch J V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 4: 443–446
   Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celligny P, Bardoantis P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibodies and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754–758
   PubMed Web of Science ®Google Scholar
• Ravetch J V, Clynes R A. Divergent roles for Fc receptors and complements in vivo. Ann Rev Immunol 1998; 16: 421–432, (1998)
   PubMed Web of Science ®Google Scholar
• Van de Winkel J GJ, Capel P J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215–221
   PubMedGoogle Scholar
• DiCarlo E, Forni G, Lollini P L, Colombo M P, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001; 97: 339–345
   PubMed Web of Science ®Google Scholar
• Colombo M P, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853–4857
   PubMed Web of Science ®Google Scholar
• Cassatella M A. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16: 21–26
   PubMedGoogle Scholar
• Hernandez-Ilizaliturri F J, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9: 5866–5873
   PubMed Web of Science ®Google Scholar
• Valerius T, Repp R, de Wit T P, Berthold S, Platzer E, Kalden J R, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI;CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993; 82: 931–939
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Valerius T, Repp R, Heijnen I A, Buhring H J, Deo Y M, et al. Pre-clinical studies with FcγRI bispecific antibodies and granulocyte stimulating factor primed neutrophils as effector cells against Her2/neu overexpressing breast cancer. Cancer Res 1997; 57: 696–701
   PubMed Web of Science ®Google Scholar
• Kushner B H, Cheung N K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73: 1936–1941
   PubMed Web of Science ®Google Scholar
• Munn D H, Cheung N KV. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987; 47: 6600–6605
   PubMed Web of Science ®Google Scholar
• Van der Kolk L E, de Haas M, Grillo-Lopez A J, Baars J W, van Oers M H. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002; 16: 693–699
   PubMed Web of Science ®Google Scholar
• Elsasser D, Valerius T, Repp R, Weiner G J, Deo Y, Kalden J R, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996; 87: 3803–3812
   PubMed Web of Science ®Google Scholar
• Kushner B H, Cheung N K. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992; 79: 1484–1490
   PubMed Web of Science ®Google Scholar
• Ottonello L, Marone P, Dapino P, Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996; 87: 5171–5178
   PubMed Web of Science ®Google Scholar
• Otonello L, Epstein A L, Dapino P, Barbera P, Marone P, Dallegri F. Monoclonal Lym-1 antibody-dependent cytotoxicity by neutrophils exposed to granulocyte-macrophage colony stimulating factor: intervention of FcγRII (CD32), CD11b/CD18 integrins, and CD66 glycoproteins. Blood 1999; 93: 3505–3511
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Jazirehi A R, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17: 621–630
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7: 709–723
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. The treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody (rituxan, rituximab) and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Davis T, Czerwinski D K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can results in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–615
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni T, Lazzari M, Borleri G M, Bernasconi S, Tedesco F, et al. Biological response of B-lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000; 96: 594–600
   PubMed Web of Science ®Google Scholar
• Ragnhammar P. Anti-tumoral effects of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Med Oncol 1996; 13: 167–176
   PubMed Web of Science ®Google Scholar
• Lopez A F, Williamson D J, Gamble J R, Begley C, Harlan J M, Klebanoff S J, et al. Recombinant human granulocyte-macrophage colony stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1987; 78: 1220–1228
   Web of Science ®Google Scholar
• Harmut J, Smith W. Cell adhesion and migration III. Leukocyte adhesion and transmigration in the liver vasculature. Am J Physiol 1997; 273: G1169–G1173
   Google Scholar
• Doerschuk C M, Tasaka S, Wang Q. CD11b/CD18- dependent and -independent neutrophil emigration in the lungs. Am J Respir Cell Mol Biol 2000; 23: 133–136
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Rieu P, Descamps-Latsha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000; 5: 617–653
   Google Scholar
• Petty H R, Todd R F. Integrins as promiscuous signal trans- duction devices. Immunol Today 1996; 17: 209–212
   PubMedGoogle Scholar
• Todd R F, Petty H R. Beta 2 (CD11b/CD18) integrins can serve as signaling partners for other leukocyte receptors. J Lab Clin Med 1997; 129: 492–498
   PubMed Web of Science ®Google Scholar
• van Spriel A B, van Ojik H H, Bakker A, Jansen M J, van de Winkel J G. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003; 101: 253–258
   PubMed Web of Science ®Google Scholar
• Curran M P, Goa K L. Pegfilgrastim. Drugs 2002; 62: 1207–1213
   PubMed Web of Science ®Google Scholar
• van der Kolk L E, Grillo-Lopez A J, Baars J W, van Oers M H. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003; 17: 1658–1664
   PubMed Web of Science ®Google Scholar
• van Spriel A B, van Ojik H H, Bakker A, Jansen M J, van de Winkel J G. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003; 101: 253–258
   PubMed Web of Science ®Google Scholar
• Venugopal P, Sivaraman S, Huang X K, Nayini J, Gregory S A, Preisler H D. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24: 411–415
   PubMed Web of Science ®Google Scholar